Entasis Therapeutics to Participate in H.C. Wainwright BioConnect 2022
Entasis Therapeutics Holdings announced its participation in the H.C. Wainwright BioConnect 2022 investor conference held virtually from January 10-13, 2022. The event will feature on-demand presentations starting January 10 and 1-on-1 investor meetings. A fireside chat is scheduled for January 10 with access via the event portal. Entasis focuses on developing novel antibacterial products targeting multidrug-resistant Gram-negative bacteria, with a pipeline including sulbactam-durlobactam for Acinetobacter baumannii and zoliflodacin for Neisseria gonorrhoeae.
- None.
- None.
WALTHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that the Company will be participating in the H.C. Wainwright BioConnect 2022 investor conference, to be held virtually from January 10-13, 2022. Details for the event and management’s participation are as follows:
H.C. Wainwright BioConnect 2022
Dates: January 10-13, 2022
Format: On-demand investor presentation beginning on January 10, 1-on-1 investor meetings
Fireside Chat: January 10, with link available through the event portal
Registration: www.hcwevents.com/bioconnect
About Entasis
Entasis is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including post Phase 3 sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0462 (targeting multiple Gram-negative pathogens including Pseudomonas aeruginosa) and ETX0282CPDP (targeting Enterobacteriaceae infections). For more information, visit www.entasistx.com.
| Entasis Contacts | |
| Company Contact | Investor Contact |
| Kyle Dow | Bruce Mackle |
| Entasis Therapeutics | LifeSci Advisors |
| (781) 810-0114 | (929) 469-3859 |
| kyle.dow@entasistx.com | bmackle@lifesciadvisors.com |
| Media Contact | |
| Brett Whelan | |
| LifeSci Communications | |
| (215) 315 3143 | |
| bwhelan@lifescicomms.com |
FAQ
When is Entasis Therapeutics participating in the H.C. Wainwright BioConnect 2022 investor conference?
What format will the H.C. Wainwright BioConnect 2022 investor conference take?
What is the focus of Entasis Therapeutics?
What are some key products in Entasis Therapeutics' pipeline?
Where can I register for the H.C. Wainwright BioConnect 2022?
